English Name: Ibrutinib
CAS No.: 936563-96-1
Molecular formula: C25H24N6O2
Molecular weight: 440.5
EINECS No.: 805-642-2
Product Description: imatinib is an oral drug used to treat adult patients with Philadelphia chromosome (BER ABL) - positive chronic myeloid leukemia (CML) in the acute phase, accelerated phase and chronic phase after interferon treatment failure. CML is a hematopoietic stem cell disease caused by abnormal DNA of stem cells in bone marrow. Abnormal DNA will produce abnormal proteins, interfere with the normal production of leukocytes in bone marrow, and eventually lead to a sharp increase in the number of leukocytes. CML is divided into three stages: chronic stage, accelerated stage and crisis stage. The average survival time of patients in crisis stage is only 2-3 months.